Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 198-201

  Schafranek, Lisa ^a,b,c   Leclercq, Tamara M ^a,b   White, Deborah L ^a,b,c   Hughes, Timothy P ^a,b,c  

^a SA Pathology ^*  (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHLOROQUINE; CLARITHROMYCIN; DASATINIB; IMATINIB;

APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; CANCER GROWTH; CELL DEATH; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL;

AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; CLARITHROMYCIN; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PYRIMIDINES; THIAZOLES;

EID: 84870929815     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.698737     Document Type: Letter

References (18)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824- 830.
2. H ochhaus A, O'B rien S G, G uilhot F,et al. S ix-year follow-up of patients receiving imatinib for the fi rst-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054- 1061.
3. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003 ; 102: 276-283. (Pubitemid 36759665)
4. B arnes D J, P alaiologou D, P anousopoulou E,et al. B cr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005 ; 65: 8912-8919. (Pubitemid 41377381)
5. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109- 1123.
6. Yang Z, Klionsky DJ. Eaten alive: A history of macroautophagy. Nat Cell Biol 2010 ; 12: 814-822.
7. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005; 5: 886- 897. (Pubitemid 41746033)
8. Mishima Y, Terui Y, Taniyama A, et al. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 2008 ; 99: 2200-2208.
9. Carella AM, Beltrami G, Pica G, et al. Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 2012 Feb 13. [Epub ahead of print]
10. Nakamura M, Kikukawa Y, Takeya M, et al. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010; 37: 815- 820.
11. L indmo K, S tenmark H. R egulation of membrane traffi c by phosphoinositide 3-kinases. J Cell Sci 2006 ; 119: 605-614.
12. Crowley LC, Elzinga BM, O'Sullivan GC, et al. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am J Hematol 2011; 86: 38- 47.
13. D egtyarev M, D e Maziè r e A, O rr C,et al. A kt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008 ; 183: 101-116.
14. Michihara A, T oda K, K ubo T,et al. D isruptive Effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull 2005 ; 28: 947-951. (Pubitemid 40880294)
15. K abeya Y, M izushima N, Y amamoto A,et al. L C3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 2004 ; 117: 2805-2812. (Pubitemid 38997262)
16. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542- 545. (Pubitemid 350060049)
17. Tang C, Schafranek L, Watkins DB, et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: Investigating resistance pathways. Leuk Lymphoma 2011 ; 52: 2139-2147.
18. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter? Blood 2009 ; 114: 5426-5435.